Vardenafil 2.5 mg is a recognized strength of conventional film-coated vardenafil hydrochloride tablets in U.S. product labeling. It is the lowest strength in the commonly labeled series of 2.5, 5, 10 and 20 mg. The existence of a strength in a prescribing label should not be mistaken for evidence that every pharmacy presently stocks an approved product in that presentation.
The 2.5 mg strength has a particularly important regulatory history. FDA determined that the former Levitra 2.5 mg product, although discontinued from marketing, had not been withdrawn for reasons of safety or effectiveness. That finding is distinct from whether a particular generic applicant has an approved and currently marketed 2.5 mg film-coated product or whether a local pharmacy can fill it. Its low numerical strength also matters in the FDA-labeled restrictions for certain strong CYP3A4 inhibitors; these can include intervals longer than the ordinary once-daily maximum.
This page is about identifying the 2.5 mg tablet and interpreting product records, not deciding who should take it. For the catalog of all strengths, visit vardenafil strengths; for clinician-led selection, use the vardenafil dosage guide.
The 2.5 mg figure describes the strength of a particular vardenafil hydrochloride film-coated tablet, not a universal dose requirement or a measurement of effectiveness. It should appear alongside the active ingredient, dosage form and product labeling when a pharmacy identifies an approved tablet.
FDA-approved manufacturers can use different tablet colors, shapes or imprints. Physical appearance can help identify a particular labeler but is not a substitute for reading the prescription and confirming the NDC or other product-specific documentation with the pharmacist.
The original Levitra brand included a 2.5 mg film-coated presentation. FDA later evaluated the status of that discontinued strength and determined it was not withdrawn for safety or effectiveness reasons. That permits discussion of the historical reference product without incorrectly implying a safety-driven regulatory removal.
However, the finding cannot be used as a claim that branded Levitra remains purchasable. The Levitra history page separates former brand status from currently approved generic applications and pharmacy supply.
DailyMed includes labels for generic vardenafil hydrochloride film-coated tablets that enumerate 2.5 mg along with other strengths. A pharmacy can use current regulatory databases to verify a specific applicant and product identity. A label is meaningful evidence for a described formulation but is not a reservation of stock.
When a seller simply writes “vardenafil 2.5 mg available,” request the actual approved product identification and a pharmacist-confirmed supply check. Brand history, approval status, NDC listing and shelf inventory are separate layers of evidence.
A searcher may be asking whether the strength existed, was approved, is currently marketed or can be purchased nearby. Those questions cannot be answered using the same record.
The table shows how to interpret each level without overstating what a database listing establishes.
| Question | Relevant evidence | What remains uncertain |
|---|---|---|
| Was 2.5 mg historically labeled? | Former Levitra labeling | Whether original brand is marketed now |
| Was brand discontinuation safety-related? | FDA withdrawal determination | Current generic supply |
| Does a generic label include 2.5 mg? | Specific product prescribing information | Applicant and marketed-package status |
| Can a pharmacy dispense it now? | Live pharmacist stock and Rx review | No guarantee until confirmed |
| Is it the right dose for a patient? | Prescriber assessment | Not determined by product listing |
The 2.5 mg film-coated presentation has a concrete role in U.S. interaction-specific labeling. For patients taking ritonavir or cobicistat, certain current vardenafil tablet labels limit exposure to no more than 2.5 mg in 72 hours; specified other CYP3A4 inhibitors also impose lower-than-usual limits and intervals. This is a product-label restriction for clinicians, not an instruction to adjust a prescription independently or a claim that all interactions can be solved with a small dose.
A dose limit does not mean that vardenafil is automatically appropriate when an interacting drug is present. Exact co-medication, formulation, liver function, blood pressure and heart-rhythm risks require individualized review. Nitrates and riociguat remain contraindicated at every strength. For the wider context see the interaction guide and the dosing framework.
The conventional 2.5 mg presentation belongs to film-coated tablet labeling. Historical Staxyn and present-day generic vardenafil ODT are distinct 10 mg dissolving formulations. These cannot be used interchangeably to obtain a desired quantity of milligrams or assumed to produce the same exposure.
An ODT prescription must be interpreted according to its own label and prescriber instructions. Read the orally disintegrating tablet guide rather than extrapolating across formulations.
Check the active ingredient, film-coated dosage form, prescribed strength, quantity and pharmacy directions. The dispensed tablet’s imprint and appearance should match the product the pharmacist identifies. If there is a discrepancy, pause and ask the pharmacist rather than guessing that an unfamiliar tablet is equivalent.
The pharmacy should explain whether it has the approved product in stock or needs to contact the prescriber about any permitted alternative. The local pharmacy guide covers the pickup verification workflow.
An automated price aggregator can display a 2.5 mg label even when no specific local pharmacy has it available. Pricing may depend on product identity and fulfillment terms, but this strength-specific guide does not present prices or rank stores.
Use the stock guide to confirm present availability and the cost-factor guide to request a fresh quote for the exact prescription.
No strength of vardenafil is appropriate for someone taking organic nitrates or riociguat. QT prolongation and certain antiarrhythmics are additional major considerations. Patients should tell their prescriber about all prescriptions, nonprescription medicines and relevant cardiac history before starting treatment.
An erection lasting longer than four hours requires urgent evaluation. Sudden vision or hearing changes require prompt medical care. Medical screening is essential regardless of the small numerical strength on a package.
Yes. U.S. film-coated vardenafil product labeling has included a 2.5 mg strength.
The original branded Levitra presentation was discontinued; historic brand records should not be treated as current stock.
FDA determined that the discontinued 2.5 mg Levitra presentation was not withdrawn for reasons of safety or effectiveness.
No guarantee can be inferred from approved-product records. Ask a licensed pharmacy to verify the specific current product and supply.
No. The 2.5 mg strength features in special U.S. label limits, including no more than 2.5 mg over 72 hours with ritonavir or cobicistat for specified film-coated products. Nitrate and riociguat contraindications remain, and only a prescriber can interpret a particular interaction.
No. The 2.5 mg strength describes a conventional film-coated tablet; ODT has different formulation-specific labeling.
Do not adjust or split a prescribed product without consulting the prescriber and pharmacist about the exact tablet and instructions.
Ask a licensed pharmacist to review the specific FDA-approved generic application and real inventory for the prescribed 2.5 mg film-coated product.